Cerulean Pharma Inc. (CERU) Stock Price Up 3.1%
Cerulean Pharma Inc. (NASDAQ:CERU) rose 3.1% on Friday . The company traded as high as $3.07 and last traded at $2.95, with a volume of 134,347 shares changing hands. The stock had previously closed at $2.86.
CERU has been the topic of a number of analyst reports. Wedbush restated an “outperform” rating and issued a $9.00 price objective on shares of Cerulean Pharma in a report on Tuesday, April 19th. Canaccord Genuity restated a “buy” rating and issued a $15.00 price objective on shares of Cerulean Pharma in a report on Wednesday, April 20th. Janney Montgomery Scott initiated coverage on shares of Cerulean Pharma in a report on Wednesday, June 1st. They issued a “buy” rating on the stock. Finally, Leerink Swann restated a “buy” rating on shares of Cerulean Pharma in a report on Sunday, June 26th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Cerulean Pharma has a consensus rating of “Buy” and an average price target of $9.28.
The firm’s market cap is $80.72 million. The stock has a 50-day moving average of $2.28 and a 200 day moving average of $2.50.
Cerulean Pharma (NASDAQ:CERU) last released its quarterly earnings data on Monday, May 2nd. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.06. On average, analysts anticipate that Cerulean Pharma Inc. will post ($1.80) earnings per share for the current fiscal year.
Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.